PillNewsroom
Pill Pushers
A daily, curated feed of drug and pharmaceutical news. FDA actions, approvals, recalls, shortages, and the companies behind them.
BioPharma DiveJul 21, 2026
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
Read at BioPharma Dive →BioPharma DiveJul 21, 2026
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”
Read at BioPharma Dive →BioPharma DiveJul 21, 2026
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
Read at BioPharma Dive →STAT — PharmaJul 21, 2026
STAT+: Anthropic deepens work with rare disease drugs
Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
Read at STAT — Pharma →
STAT — PharmaJul 21, 2026
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
Novo Nordisk sued Eli Lilly for allegedly running “deceptive” ads to make its obesity and diabetes drugs appear more effective
Read at STAT — Pharma →
STAT — PharmaJul 21, 2026
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
Read at STAT — Pharma →
STAT — PharmaJul 21, 2026
STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
A coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.
Read at STAT — Pharma →
BioPharma DiveJul 20, 2026
Pain drugmaker Latigo outlines plans to go public
The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
Read at BioPharma Dive →STAT — PharmaJul 20, 2026
STAT+: The next step of site-neutral, and a fiery PBM hearing
Medicare proposes to reduce payments to hospitals for certain drugs and imaging services.
Read at STAT — Pharma →
BioPharma DiveJul 20, 2026
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
Read at BioPharma Dive →BioPharma DiveJul 20, 2026
[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.
Read at BioPharma Dive →STAT — PharmaJul 20, 2026
STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
Bristol Myers Squibb is the third drugmaker in nine months to announce it is building the largest AI supercomputer in the life sciences industry.
Read at STAT — Pharma →
STAT — PharmaJul 20, 2026
STAT+: State audit of Medicaid records points to methods used by PBMs to obscure drug costs
An audit of state Medicaid records revealed how PBMs are using complicated tactics for handling prescription drug claims that ultimately overcharge taxpayers.
Read at STAT — Pharma →
FDA — Press ReleasesJul 17, 2026
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemi
Read at FDA — Press Releases →STAT — PharmaJul 17, 2026
STAT+: The end for GSK’s chronic cough treatment
Sonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The Readout
Read at STAT — Pharma →
BioPharma DiveJul 17, 2026
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.
Read at BioPharma Dive →BioPharma DiveJul 17, 2026
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
Read at BioPharma Dive →STAT — PharmaJul 17, 2026
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Read at STAT — Pharma →
STAT — PharmaJul 17, 2026
STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
The number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026
Read at STAT — Pharma →STAT — PharmaJul 17, 2026
STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
Sonothera is developing a new way to deliver genes into cells that, if borne out, could have a big impact on muscular dystrophy and other diseases.
Read at STAT — Pharma →
Sources: reputable US pharmaceutical news outlets and FDA press releases, via their public feeds. Links open the publisher's site and carry no endorsement. Pillstats is a referrer, not a republisher.